Back to top

Exelixis (EXEL) Gets a Buy from Goldman Sachs

In a report released today, Paul Choi from Goldman Sachs maintained a Buy rating on Exelixis, with a price target of $64.00. Choi covers the Health...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Exelixis, Inc. (EXEL)